Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma (Q38090691)

28 August 2017

Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma (English)

1 reference

28 August 2017

1 reference

1

1 reference

28 August 2017

Giuseppa Penna

2

1 reference

28 August 2017

Andrea Alonci

3

1 reference

28 August 2017

Sabina Russo

4

1 reference

28 August 2017

Bruna Greve

5

1 reference

28 August 2017

Vanessa Innao

6

1 reference

28 August 2017

Viviana Minardi

7

1 reference

28 August 2017

Caterina Musolino

8

1 reference

28 August 2017

17 April 2013

1 reference

European Journal of Haematology

28 August 2017

1 reference

28 August 2017

90

1 reference

28 August 2017

441-468

1 reference

28 August 2017

6

1 reference

Multiple myeloma: improved outcomes with new therapeutic approaches

28 August 2017

1 reference

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study

21 January 2018

1 reference

Humoral immunotherapy of multiple myeloma: perspectives and perplexities.

21 January 2018

1 reference

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

21 January 2018

1 reference

Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma

21 January 2018

1 reference

Monoclonal antibodies: versatile platforms for cancer immunotherapy

21 January 2018

1 reference

Targeted therapies in multiple myeloma

21 January 2018

1 reference

Anti-CD20 monoclonal antibody therapy in multiple myeloma.

21 January 2018

1 reference

CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma.

21 January 2018

1 reference

Therapy strategies for multiple myeloma: current status

21 January 2018

1 reference

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

21 January 2018

1 reference

CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma

21 January 2018

1 reference

2B4 (CD244) and CS1: novel members of the CD2 subset of the immunoglobulin superfamily molecules expressed on natural killer cells and other leukocytes

21 January 2018

1 reference

Phospholipase C-gamma 2 is a critical signaling mediator for murine NK cell activating receptors

21 January 2018

1 reference

CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells

21 January 2018

1 reference

Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma

21 January 2018

1 reference

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

21 January 2018

1 reference

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma

21 January 2018

1 reference

Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma

21 January 2018

1 reference

The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo

21 January 2018

1 reference

Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells

21 January 2018

1 reference

Antibody-maytansinoid conjugates for the treatment of myeloma

21 January 2018

1 reference

Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients

21 January 2018

1 reference

Human CD38: a glycoprotein in search of a function

21 January 2018

1 reference

Human CD38: a (r)evolutionary story of enzymes and receptors

21 January 2018

1 reference

Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo

21 January 2018

1 reference

Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients.

21 January 2018

1 reference

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

21 January 2018

1 reference

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

21 January 2018

1 reference

CD40, but not CD154, expression on B cells is necessary for optimal primary B cell responses

21 January 2018

1 reference

Sequence analysis identifies TTRAP, a protein that associates with CD40 and TNF receptor-associated factors, as a member of a superfamily of divalent cation-dependent phosphodiesterases

21 January 2018

1 reference

The TNF superfamily members LIGHT and CD154 (CD40 ligand) costimulate induction of dendritic cell maturation and elicit specific CTL activity

21 January 2018

1 reference

B cell receptor (BCR) cross-talk: CD40 engagement creates an alternate pathway for BCR signaling that activates I kappa B kinase/I kappa B alpha/NF-kappa B without the need for PI3K and phospholipase C gamma

21 January 2018

1 reference

COX-2 and CCR2 induced by CD40 ligand and MCP-1 are linked to VEGF production in endothelial cells

21 January 2018

1 reference

Cooperation of multiple signaling pathways in CD40-regulated gene expression in B lymphocytes

21 January 2018

1 reference

Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma

21 January 2018

1 reference

Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma

21 January 2018

1 reference

The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells

21 January 2018

1 reference

A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40.

21 January 2018

1 reference

Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications

21 January 2018

1 reference

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

21 January 2018

1 reference

A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma

21 January 2018

1 reference

In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells

21 January 2018

1 reference

Expression of the natural killer (NK) cell-associated antigen CD56(Leu-19), which is identical to the 140-kDa isoform of N-CAM, in neural and skeletal muscle cells and tumors derived therefrom

21 January 2018

1 reference

Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.

21 January 2018

1 reference

Regulation of the CD56 promoter and its association with proliferation, anti-apoptosis and clinical factors in multiple myeloma.

21 January 2018

1 reference

Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation

21 January 2018

1 reference

Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1.

21 January 2018

1 reference

Insulin-like growth factor I induces MDM2-dependent degradation of p53 via the p38 MAPK pathway in response to DNA damage

21 January 2018

1 reference

Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma

21 January 2018

1 reference

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.

21 January 2018

1 reference

Inhibition of IGF-1 signalling enhances the apoptotic effect of AS602868, an IKK2 inhibitor, in multiple myeloma cell lines.

21 January 2018

1 reference

A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45.

21 January 2018

1 reference

Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies

21 January 2018

1 reference

Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma

21 January 2018

1 reference

Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells

21 January 2018

1 reference

A defucosylated anti-CD317 antibody exhibited enhanced antibody-dependent cellular cytotoxicity against primary myeloma cells in the presence of effectors from patients

21 January 2018

1 reference

Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function

21 January 2018

1 reference

Hu Ly-M3--a human leukocyte antigen

21 January 2018

1 reference

CD48 as a novel molecular target for antibody therapy in multiple myeloma

21 January 2018

1 reference

Structures of two classes of MHC molecules elucidated: crucial differences and similarities.

21 January 2018

1 reference

Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies

21 January 2018

1 reference

21 January 2018

Novel immunotherapies

1 reference

Targeting cell surface β2 -microglobulin by pentameric IgM antibodies

21 January 2018

1 reference

Protective CD8 T cell memory is impaired during chronic CD70-driven costimulation.

21 January 2018

1 reference

Constitutive CD27/CD70 interaction induces expansion of effector-type T cells and results in IFNgamma-mediated B cell depletion

21 January 2018

1 reference

Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities

21 January 2018

1 reference

Isolation of cDNA clones for the p33 invariant chain associated with HLA-DR antigens

21 January 2018

1 reference

Macrophage migration inhibitory factor elicits an angiogenic phenotype in human ectopic endometrial cells and triggers the production of major angiogenic factors via CD44, CD74, and MAPK signaling pathways

21 January 2018

1 reference

CD74 is expressed by multiple myeloma and is a promising target for therapy

21 January 2018

1 reference

Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies

21 January 2018

1 reference

Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines

21 January 2018

1 reference

Milatuzumab - a promising new immunotherapeutic agent.

21 January 2018

1 reference

IFN-gamma enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3.

21 January 2018

1 reference

A single-chain Fv diabody against human leukocyte antigen-A molecules specifically induces myeloma cell death in the bone marrow environment

21 January 2018

1 reference

Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells

21 January 2018

1 reference

Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations

21 January 2018

1 reference

2D7 diabody bound to the alpha2 domain of HLA class I efficiently induces caspase-independent cell death against malignant and activated lymphoid cells

21 January 2018

1 reference

The CD2-subset of the Ig superfamily of cell surface molecules: receptor-ligand pairs expressed by NK cells and other immune cells

21 January 2018

1 reference

Identification of Grb2 as a novel binding partner of the signaling lymphocytic activation molecule-associated protein binding receptor CD229.

21 January 2018

1 reference

Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma

21 January 2018

1 reference

CD200 is a new prognostic factor in multiple myeloma

21 January 2018

1 reference

PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma

21 January 2018

1 reference

A means to a DNA end: the many roles of Ku.

21 January 2018

1 reference

DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation

21 January 2018

1 reference

Interplay of p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability and development

21 January 2018

1 reference

DNA double-strand breaks: signaling, repair and the cancer connection

21 January 2018

1 reference

Ku autoantigen: a multifunctional DNA-binding protein

21 January 2018

1 reference

A pivotal role for Mcl-1 in Bortezomib-induced apoptosis

21 January 2018

1 reference

Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.

21 January 2018

1 reference

Evidence for the secretion of an osteoclast stimulating factor in myeloma.

21 January 2018

1 reference

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

21 January 2018

1 reference

Interleukin-6 signaling pathway in targeted therapy for cancer

21 January 2018

1 reference

Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study

21 January 2018

1 reference

Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death

21 January 2018

1 reference

Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma

21 January 2018

1 reference

Humanized anti-interleukin-6 receptor monoclonal antibody induced apoptosis of fresh and cloned human myeloma cells in vitro

21 January 2018

1 reference

Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor

21 January 2018

1 reference

Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects

21 January 2018

1 reference

A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma

21 January 2018

1 reference

The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells

21 January 2018

1 reference

The role of microenvironment in tumor angiogenesis

21 January 2018

1 reference

Targeting signalling pathways for the treatment of multiple myeloma

21 January 2018

1 reference

Targeting the tumor microenvironment: focus on angiogenesis

21 January 2018

1 reference

Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy

21 January 2018

1 reference

Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary systemic amyloidosis.

21 January 2018

1 reference

For investigational targeted drugs, combination trials pose challenges

21 January 2018

1 reference

Bevacizumab attenuates major signaling cascades and eIF4E translation initiation factor in multiple myeloma cells

21 January 2018

1 reference

Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial

21 January 2018

1 reference

Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy.

21 January 2018

1 reference

Epidermal growth factor receptor targeting in cancer

21 January 2018

1 reference

Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody

21 January 2018

1 reference

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells

21 January 2018

1 reference

An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis.

21 January 2018

1 reference

Initial genome sequencing and analysis of multiple myeloma

21 January 2018

1 reference

MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells.

21 January 2018

1 reference

Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma.

21 January 2018

1 reference

Denosumab in osteoporosis and oncology

21 January 2018

1 reference

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

21 January 2018

1 reference

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

21 January 2018

1 reference

A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.

21 January 2018

1 reference

An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma

21 January 2018

1 reference

Osteonecrosis of the jaw in a patient on Denosumab

21 January 2018

1 reference

Denosumab: the era of targeted therapies in bone metastatic diseases

21 January 2018

1 reference

In silico investigations of the anti-catabolic effects of pamidronate and denosumab on multiple myeloma-induced bone disease

21 January 2018

1 reference

The role of Dickkopf-1 in bone development, homeostasis, and disease

21 January 2018

1 reference

Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo

21 January 2018

1 reference

Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.

21 January 2018

1 reference

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

21 January 2018

1 reference

Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma

21 January 2018

1 reference

Regulation of cellular and system function by activin.

21 January 2018

1 reference

Activin A is an essential cofactor for osteoclast induction.

21 January 2018

1 reference

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

21 January 2018

1 reference

Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival

21 January 2018

1 reference

The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature

21 January 2018

1 reference

Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model

21 January 2018

1 reference

BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone

21 January 2018

1 reference

Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment

21 January 2018

1 reference

Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study

21 January 2018

1 reference

Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts

21 January 2018

1 reference

Antibody targeting of B-cell maturation antigen on malignant plasma cells

21 January 2018

1 reference

Following a TRAIL: update on a ligand and its five receptors

21 January 2018

1 reference

Death to the bad guys: targeting cancer via Apo2L/TRAIL.

21 January 2018

1 reference

Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy.

21 January 2018

1 reference

HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo

21 January 2018

1 reference

Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells

21 January 2018

1 reference

The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells

21 January 2018

1 reference

Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2.

21 January 2018

1 reference

21 January 2018

The B7 family revisited

1 reference

Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway.

21 January 2018

1 reference

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma

21 January 2018

1 reference

Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis

21 January 2018

1 reference

The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications

21 January 2018

1 reference

Multiple myeloma in a murine syngeneic model:modulation of growth and angiogenesis by a monoclonal antibody to kininogen

21 January 2018

1 reference

Characterization of clonogenic multiple myeloma cells

21 January 2018

1 reference

Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.

21 January 2018

1 reference

Mutation analysis of the FAS and TNFR apoptotic cascade genes in hematological malignancies.

21 January 2018

1 reference

Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin

21 January 2018

1 reference

Monoclonal antibodies in the treatment of multiple myeloma

21 January 2018

1 reference

Drug-conjugated monoclonal antibodies for the treatment of cancer

21 January 2018

1 reference

Potent antibody drug conjugates for cancer therapy

21 January 2018

1 reference

Antibody-based therapies in multiple myeloma

21 January 2018

1 reference

Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.

21 January 2018

1 reference

CD20-Directed Serotherapy in Patients With Multiple Myeloma: Biologic Considerations and Therapeutic Applications

21 January 2018

1 reference

The Role of Platelet/Endothelial Cell Adhesion Molecule 1 (CD31) and CD38 Antigens in Marrow Microenvironmental Retention of Acute Myelogenous Leukemia Cells

21 January 2018

1 reference

Translocation of Ku86/Ku70 to the multiple myeloma cell membrane

21 January 2018

1 reference

Synergistic induction of growth arrest and apoptosis of human myeloma cells by the IL-6 super-antagonist Sant7 and Dexamethasone

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/EJH.12107

1 reference

28 August 2017

1 reference